Prescriber-Level Responses to the 2018–2019 Valsartan, Irbesartan, and Losartan Recalls and Drug Shortages
In this prescriber level, national study, substitutions to other ARBs mitigated decreases in valsartan fills after it was recalled. There were no spillovers to non-ARB anti-hypertensives. The availability of close substitutes during drug shortages may mitigate gaps in access for prescribers and their patients.
Authors
- Eric T. Roberts (ORCID: https://orcid.org/0000-0002-7439-0799)
- Katie J. Suda
- Chester B. Good (ORCID: https://orcid.org/0000-0003-4388-4558)
- Julie M. Donohue
- Lindsay M. Sabik (ORCID: https://orcid.org/0000-0002-0613-4929)
- Katherine Callaway Kim (ORCID: https://orcid.org/0000-0002-2924-6165)
Institutions
- University of Pittsburgh (US)
- VA Pittsburgh Healthcare System (US)
- UPMC Center for High Value Health Care (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Medical Care
- Published
- 2025-09-19
- DOI
- https://doi.org/10.1097/mlr.0000000000002209
- Primary Topic
- Blood Pressure and Hypertension Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00